Lepirudin prevents lethal effects of Shiga toxin in a canine model

Summary

Microvascular thrombosis is a major cause of organ damage in Shiga toxin-mediated hemolytic uremic syndrome (Stx-HUS). In vitro and clinical studies implicate thrombin-mediated mechanisms in the pathogenesis of Stx microvascular thrombosis. In a greyhound model, administration of 0.03μg/kg to 0.05μg/kg Stx1 or Stx2 causes severe bloody diarrhea and HUS with microvascular thrombosis requiring humane euthanasia within 65 hours. Using a greyhound model of Stx-HUS we analyzed early hemostatic changes, and tested the hypothesis that thrombin blockade with lepirudin would prevent lethal Stx effects. Two Stx1-exposed greyhounds were analyzed for hemostatic changes prior to onset of clinical manifestations. Serial hemostasis studies after Stx1 challenge revealed trends of increased aPTT, fibrinogen levels, and prothrombin fragment 1+2, and appearance of abnormally large von Willebrand factor multimers. Three greyhounds were anticoagulated with lepirudin to maintain activated partial thromboplastin times (aPTT) >2.5-fold normal, followed by administration of Stx2 and observation of clinical responses. Among the 3 lepirudin-treated, Stx2-challenged greyhounds, one developed severe illness requiring euthanasia. Remarkably, 2 of the 3 greyhounds developed only hypersalivation and restlessness that resolved (P <.03 compared to 14 historical controls). These two greyhounds were clinically, hematologically and biochemically normal 74 hours after Stx administration, well beyond the time of euthanasia of any previous greyhound. This study suggests that greyhounds exposed to Stx develop procoagulant changes similar to humans, and that thrombin may be a critical factor in the pathogenesis and treatment of Stx-HUS.

Keywords

Shiga toxin - lepirudin - thrombotic microangiopathy - procoagulant

• References

• 1 Lentz SR, Tsiang M, Sadler JE. Regulation of thrombomodulin by tumor necrosis factoralpha: Comparison of transcriptional and posttranscriptional mechanisms. Blood 1991; 77 (03) 542-550.
• 2 Kalk E. Is tissue factor an early trigger in the pathogenesis of haemolytic uremic syndrome? (abstract). In: 5th International Symposium on ‘Shiga Toxin (Verocytotoxin)-Producing Escherichia coli Infections’; 2003. Edinburgh, Scotland: VTEC; 2003: 38.
• 3 Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740.
• 4 Scarpati EM, Sadler JE. Regulation of endothelial cell coagulant properties. Modulation of tissue factor, plasminogen activator inhibitors, and thrombomodulin by phorbol 12- myristrate 13-acetate and tumor necrosis factor. J Biol Chem 1996; 264 (34) 20705-13.
• 5 Tsai H, Chandler L, Sarode R. et al. von Willebrand factor and von Willebrand factorcleaving metalloproteinase activity in Escherichia coli 0157:H7-associated hemolytic uremic syndrome. Pediatr Res 2001; 49 (05) 653-659.
• 6 Habib R. Pathology of the hemolytic uremic syndrome. In: Kaplan B, Trompeter R, Moake J. editors. Hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. New York: Marcel Dekker, Inc; 1992: 315-353.
• 7 Rose P, Chant I. Hematology of the hemolytic uremic syndrome. In: Kaper J, O’Brien A. editors. Escherichia coli 0157:H7 and other shiga toxin-producing E. coli strains. Washington, DC: ASM Press; 1998: 293-302.
• 8 Gordjani N, Sutor A, Zimmerhackl L. et al. Hemolytic uremic syndromes in childhood. Semin Thromb Hemost 1997; 23 (03) 281-293.
• 9 Chandler W, Jelacic S, Boster D. et al. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med 2002; 346: 23-32.
• 10 Proesmans W, Eeckels R. Treatment of hemolytic uremic syndrome with antithrombotic agents. In: Kaplan B, Trompeter R, Moake J. editors. Hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. New York: Marcel Dekker, Inc; 1992: 421-430.
• 11 Geet C, Proesmans W, Arnout J. et al. Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome. Kidney Int 1998; 54: 1324-1330.
• 12 Wallis R. Hirudins: from leeches to man. Semin Thromb Hemost 1996; 22 (02) 185-196.
• 13 Hertzke D, Cowan L, Schoning P. et al. Glomerular ultrastructural lesions of idiopathic cutaneous and renal glomerular vasculopathy of greyhounds. Vet Pathol 1995; 32: 451-459.
• 14 Cowan L, Hertzke D, Fenwick B. et al. Clinical and clinicopathological abnormalities in greyhounds with cutaneous and renal glomerular vasculopathy: 18 cases (1992-1994). J Am Vet Med Assoc 1997; 210 (06) 789-793.
• 15 Fenwick b, Cowan L. Canine model of hemolytic uremic syndrome. In: Kaper J, O’Brien A. editors. Escherichia coli0157:H7 and other shiga toxin producing E. coli strains. 1 ed. Washington, DC: American Society for Microbiology; 1998: 268-277.
• 16 Montgomery RR, Johnson J. Specific factor VIII-related antigen fragmentation: an in vivo and in vitro phenomenon. Blood 1982; 60 (04) 930-939.
• 17 Boerlin P, McEwen S, Boerlin-Petzold F. et al. Associations between virulence factors of shiga toxin-producing Escherichia coli and disease in humans. Journal of Clinical Microbiology 1999; 37: 497-503.
• 18 Matussek A, Lauber J, Bergau A. et al. Molecular and functional analysis of Shiga toxin induced response patterns in human vascular endothelial cells. Blood 2003; 102: 1323-1332.
• 19 Nevard C, Jurd K, Lane D. et al. Activation of coagulation and fibrinolysis in childhood diarrhoea-associated haemolytic uraemic syndrome. Thromb Haemost 1997; 78: 1450-1455.
• 20 Chin A, Vergnolle N, MacNaughton W. et al. Proteinase-activated receptor 1 activation induces epithelial apoptosis and increases intestinal permeability. Proc Natl Acad Sci USA 2003; 100: 11104-9.
• 21 Siegler R, Pysher T, Tesh V. et al. Prophylactic heparinization is ineffective in a primate model of hemolytic uremic syndrome. Pediatr Nephrol 2002; 17: 1053-1058.
• 22 Hermida J, Montes R, Paramo J. et al. Endotoxin-induced disseminated intravascular coagulation in rabbits: effect of recombinant hirudin on hemostatic parameters, fibrin deposits, and mortality. J Lab Clin Med 1998; 131: 77-83.
• 23 Jackson C, Bailey B, Shetler T. Pharmacological profile of recombinant, human activated protein C (LY203638) in a canine model of coronary artery thrombosis. JPET 2000; 295: 967-971.
• 24 Gunzer F, Hennig-Pauka I, Waldemann K-H. et al. Gnotobiotic piglets develop thrombotic microangiopathy after oral infection with enterohemorrhagic Escherichia coli. Am J Clin Pathol 2002; 118: 364-375.
• 25 Taylor F, Tesh V, DeBault L. et al. Characterization of the baboon responses to shiga-like toxin. Am J Pathol 1999; 154 (04) 1285-1299.
• 26 Taylor C, Williams J, Lote C. et al. A laboratory model of toxin-induced hemolytic uremic syndrome. Kidney Int 1999; 55: 1367-1374.